Key points for the development of mouse immunogenicity test as potency assay for acellular pertussis vaccines

Biologicals

Volumn 28, Issue 4, 2000, Pages 217-225

  André, Murielle ^a   Poirier, Bertrand ^a   Bornstein, Nicole ^a   Marmonier, Denis ^a   El Zaouk, Annie ^b   Fuchs, Florence ^a  

^a Healthy Pigs Production and Experimentation Section   (France)

^b Unité De Pharmaco Toxicologie   (France)

Author keywords

Acellular pertussis vaccine; Batch release; Potency assay; Statistics

Indexed keywords

PERTUSSIS VACCINE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; FEMALE; IMMUNOGENICITY; MOUSE; NONHUMAN; PERTUSSIS; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; VACCINATION; VALIDATION PROCESS;

ANIMALIA;

EID: 0034462140     PISSN: 10451056     EISSN: None     Source Type: Journal    
DOI: 10.1006/biol.2000.0259     Document Type: Article

References (16)

1. Preparation and composition of acellular pertussis vaccines. ConsideratiOn of potential effects on vaccine efficacy
2. The current status of acellular pertussis vaccines
3. New acellular pertussis-containing paediatric combined vaccines
4. Approaches to the control of acellular pertussis vaccines
5. A consideration of control requirements for acellular pertussis vaccines
6. Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: Value of laboratory tests as predictors of clinical performance
7. Guidelines for the production and control of the acellular pertussis component of monovalent or combined vaccines
8. Immunogenicity issues in the quality control of the new acellular pertussis vaccines
9. Intranasal murine model of Bordetella pertussis infection. I. Prediction of protection in human infants by acellular vaccines
10. An aerosol challenge model of Bordetella pertussis infection as a potential bioassay for acellular pertussis vaccines